Evidence map›Paper›PMID 22744906›Full record

ArticleStatistics in medicine2012

Frailty modeling of age-incidence curves of osteosarcoma and Ewing sarcoma among individuals younger than 40 years.

Morten Valberg, Tom Grotmol, Steinar Tretli, Marit B Veierød, Susan S Devesa, Odd O Aalen

Open access · bronzeAbstract read
In one paragraph

Article in Statistics in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Morten ValbergDepartment of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. morten.valberg@medisin.uio.no
Tom Grotmol
Steinar Tretli
Marit B Veierød
Susan S Devesa
Odd O Aalen
University of Oslo · NOCancer Registry of Norway · NODivision of Cancer Epidemiology and Genetics

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

The Armitage-Doll model with random frailty can fail to describe incidence rates of rare cancers influenced by an accelerated biological mechanism at some, possibly short, period of life. We propose a new model to account for this influence. Osteosarcoma and Ewing sarcoma are primary bone cancers with characteristic age-incidence patterns that peak in adolescence. We analyze Surveillance, Epidemiology and End Result program incidence data for whites younger than 40 years diagnosed during the period 1975-2005, with an Armitage-Doll model with compound Poisson frailty. A new model treating the adolescent growth spurt as the accelerated mechanism affecting cancer development is a significant improvement over that model. We also model the incidence rate conditioning on the event of having developed the cancers before the age of 40 years and compare the results with those predicted by the Armitage-Doll model. Our results support existing evidence of an underlying susceptibility for the two cancers among a very small proportion of the population. In addition, the modeling results suggest that susceptible individuals with a rapid growth spurt acquire the cancers sooner than they otherwise would have if their growth had been slower. The new model is suitable for modeling incidence rates of rare diseases influenced by an accelerated biological mechanism.

Indexed as

AdolescentAdolescent DevelopmentAdultAge DistributionBone NeoplasmsChildChild, PreschoolDisease SusceptibilityFemaleHumansIncidenceInfantInfant, NewbornMaleModels, BiologicalOsteosarcoma

Identifiers

PMID22744906
PMCPMC4052707
OpenAlexW2147809374

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.